Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016
Published Jun 28, 2016
62 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016, provides in depth analysis on Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted pipeline therapeutics.

The report provides comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12)
- The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and mol

  
Source:
Document ID
GMDHC0171TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Overview71
Therapeutics Development84
  Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Products under Development by Stage of Development81
  Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Products under Development by Therapy Area91
  Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Products under Development by Indication102
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Products under Development by Companies142
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Products under Development by Universities/Institutes162
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Therapeutics Assessment187
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Companies Involved in Therapeutics Development254
  Juventas Therapeutics, Inc.251
  Momenta Pharmaceuticals, Inc.261
  Noxxon Pharma AG271
  TikoMed AB281
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Drug Profiles2918
  Genistein Drug Profile291
  IBsolvMIR Drug Profile301
  JVS-100 Drug Profile315
  necuparanib Drug Profile363
  olaptesed pegol Drug Profile394
  Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency Drug Profile431
  Small Molecules to Inhibit CXCL12 for Metastatic Cancer Drug Profile441
  Synthetic Peptide to Target CXCR4 and SDF-1 for HIV Drug Profile451
  Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease Drug Profile461
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Dormant Projects472
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Featured News &Press Releases4912
  Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO491
  May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting501
  Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease501
  Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium511
  Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study521
  Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study521
  Jun 16, 2015: Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy531
  Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer531
  May 26, 2015: Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment542
  May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting561
  Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference561
  Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer571
  Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia581
  Nov 12, 2014: Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions591
  Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer592
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Stromal-Cell-Derived-Factor-1-C-X-C-Motif-Chemokine-12-or-Intercrine-Reduced-in-Hepatomas-or-SDF1-or-Pre-B-cell-Growth-Stimulating-Factor-or-CXCL12-Pipeline-Review-H1-2016-2088-16059>
  
APA:
Global Markets Direct - Market Research. (2016). Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Stromal-Cell-Derived-Factor-1-C-X-C-Motif-Chemokine-12-or-Intercrine-Reduced-in-Hepatomas-or-SDF1-or-Pre-B-cell-Growth-Stimulating-Factor-or-CXCL12-Pipeline-Review-H1-2016-2088-16059>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.